TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Energy Income Fund (TSX – ENI.UN) (the “Fund”) announces the following distributions per unit will be declared payable on each distribution payment date to unitholders of record on the distribution record date indicated below:Record Date Payment Date Amount (C$ per unit)31-Jan-26 17-Feb-26 $0.0128-Feb-26 16-Mar-26 $0.0131-Mar-26 15-Apr-26 $0.0130-Apr-26 15-May-26 $0.0131-May-26 15-Jun-26 $0.0130-Jun-26 15-Jul-26 $0.0131-Jul-26 17-Aug-26 $0.0131-Aug-26 15-Sep-26 $0.0130-Sep-26 15-Oct-26 $0.0131-Oct-26 16-Nov-26 $0.0130-Nov-26 15-Dec-26 $0.0131-Dec-26 15-Jan-27 $0.01For further information, please contact Artemis Investment Management Limited, the manager of the Fund, at (416) 934-7455 or visit our website at www.artemisfunds.ca.

TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Citadel Income Fund (TSX – CTF.UN) (the “Fund”) announces the following distributions per unit will be declared payable on each distribution payment date to unitholders of record on the distribution record date indicated below:Record Date Payment Date Amount (C$ per unit)31-Jan-26 17-Feb-26 $0.0228-Feb-26 16-Mar-26 $0.0231-Mar-26 15-Apr-26 $0.0230-Apr-26 15-May-26 $0.0231-May-26 15-Jun-26 $0.0230-Jun-26 15-Jul-26 $0.0231-Jul-26 17-Aug-26 $0.0231-Aug-26 15-Sep-26 $0.0230-Sep-26 15-Oct-26 $0.0231-Oct-26 16-Nov-26 $0.0230-Nov-26 15-Dec-26 $0.0231-Dec-26 15-Jan-27 $0.02For further information, please contact Artemis Investment Management Limited, the manager of the Fund, at (416) 934-7455 or visit our website at www.artemisfunds.ca.

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today highlighted upcoming milestones and recent corporate updates. “2025 was marked by robust execution at Xilio as we delivered on key priorities...

‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 million ‒ ‒ Unaudited Cash and Short-term Investments of Approximately $148 million ‒   BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) — CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter 2025 and full-year 2025 results, and provides guidance and an update on its business. These include the following key updates:CorMedix announces preliminary, unaudited financial results for Q4 and FY 2025, including net revenue of approximately $127 million and...

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter Preliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025 Potential best-in-class RSV antibody VBY329 nominated for preclinical development Preclinical measles mAb candidate selection targeted for 1H 2026 for treatment and prevention of measles Further updates to be provided in conjunction with Form 10-K filing and upcoming ordinary quarterly reportingNEW HAVEN, Conn., Jan....

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) — 21shares, one of the world’s largest issuers of cryptocurrency exchange traded products (ETPs), today announced the following distribution for the 21shares Ethereum ETF (TETH) for staking rewards earned from its ETH holdings.Ticker Name Distribution Ex/Record Date Payable DateTETH 21shares Ethereum ETF $0.010378 per share January 8, 2026 January 9, 2026About 21shares 21shares is one of the world’s leading cryptocurrency exchange traded product (ETP) providers and offers one of the largest suites of crypto ETPs in the market. The company was founded to make cryptocurrency more accessible to investors, and to bridge the gap between traditional finance and decentralized finance. 21shares listed the world’s first physically-backed crypto ETP in 2018, building a seven-year track record...

TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Matachewan Consolidated Mines, Limited (“Matachewan” or the “Company”) (TSX-V:MCM.A-X) today announced that the Board of Directors of the Company (the “Board”) has declared a special one-time distribution of cash (the “Cash Distribution”) and a special one-time distribution of common shares of Taranis Resources Inc. (“Taranis Shares”) that are held by the Company (the “Share Distribution”, and, collectively with the Cash Distribution, the “Distributions”) to its shareholders (the “Shareholders”) of record at the close of business on January 14, 2026 (the “Record Date”). The Distributions will be made on January 22, 2026 (the “Distribution Date”). After careful consideration of the potential alternatives, the Board determined that it is in the best interest of the Company for it to make...

January 2026 Monthly Dividend of $0.12 Per Share of Common Stock Estimated Fourth Quarter 2025 Results and MBS Portfolio Characteristics as of December 31, 2025 to be Released January 14, 2026 Year End and Fourth Quarter 2025 Results to be Released January 29, 2026VERO BEACH, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) — Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of January 2026. The dividend of $0.12 per share will be paid February 26, 2026, to holders of record of the Company’s common stock on January 30, 2026, with an ex-dividend date of January 30, 2026. The Company plans on announcing its next common stock dividend on February 11, 2026. The Company intends to make regular monthly cash distributions to its holders...

TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) — (TSX: PIC.A; PIC.PR.A) Premium Income Corporation (the “Fund”) is pleased to announce its intention to complete a share split of its class A shares (the “Share Split”) due to the Fund’s strong performance. Class A shareholders of record at the close of business on January 13, 2026 will receive 10 additional class A shares for every 100 class A shares held, pursuant to the Share Split. The Share Split is subject to the approval by the Toronto Stock Exchange (the “TSX”). The Fund has also declared an increase to the monthly distributions payable to class A shareholders of $0.09 per share from $0.08 per share. As a result of the Share Split and monthly distribution increase, the total dollar amount of distributions to be paid to class A shareholders is expected to increase by approximately...

Date: 6 January 2026 Release: After closing of Euronext Please open the following link to read the full report including annexes:AttachmentPR 2026 01 06 UK Heading